Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
|Articles|December 2, 2015

Express Scripts to Offer $1 Daraprim Alternative

Express Scripts announced its plan to offer a $1 alternative to Daraprim, a generic drug used for the treatment of toxoplasmosis.

On Dec. 1, 2015 Express Scripts announced its plan to partner with Imprimis Pharmaceuticals to create an inexpensive alternative to Daraprim, a 62-year-old generic drug used for the treatment of toxoplasmosis.

Toxoplasmosis is a disease caused by single-celled parasite, Toxoplasma gondii, which can cause death from foodborne illness in those with weakened immune systems. Daraprim is primarily used to treat patients with compromised immune systems, such as those with HIV, cancer patients, and pregnant women.

Daraprim made headlines in September 2015, when Martin Shkreli, former hedge fund manager and current head of Turing Pharmaceuticals, hiked the price of the medication from $13.50 to $750 per pill. The hike spurred the House Committee on Oversight and Government Reform to send a letter to Shkreli, requesting information on the nearly 5000% increase.

In an interview with CBS News, Shkreli denied that that the company’s decision to raise the price of the drug was drastic.

“Well, it depends on how you define ‘so drastically,'” he said. “Because the drug was unprofitable at the former price, so anyone selling it would be losing money. And at this price it’s a reasonable profit. Not excessive at all.”  

Express Scripts is now offering a compounded oral formulation of pyrimethamine, the same active ingredient as Daraprim, for $1 per capsule. The FDA prohibits exact replication of drugs like Daraprim, and this new formulation contains the addition of Vitamin B and leucovorin. The company says the drug will be processed as early as the beginning of December 2015 for patients.

In a press release, the pharmacy benefit manager (PBM) said it is working with the Infectious Disease Society of America (IDSA) and the HIV Medicine Association (HIVMA) to assist physicians in prescribing the Daraprim alternative. Physicians will be required to submit prescriptions for the new compound directly to Imprimis.

According to a report by New York Times, while the price of Daraprim has become a highly debated topic in the pharmaceutical industry, it is estimated that only approximately 2000 patients in the United States use Daraprim yearly. In 2014, there were only 350 patients that were prescribed Daraprim under Express Scripts plans. 

Source: Express Scripts


Related to this article

The BioPharm Brief: FDA’s Fast-Track Pilot Reportedly Stalls, a Long-Acting Bispecific for Atopic Dermatitis, and a Twice-Yearly Obesity Approach
FDA has reportedly shelved its Commissioner’s National Priority Voucher pilot and paused publishing complete response letters, Zai Lab’s IL-13/IL-31Rα bispecific ZL-1503 shows a 40- to 50-day half-life that points to dosing every 12 weeks, and Wave Life Sciences reports 1-year INLIGHT data for its INHBE-silencing siRNA WVE-007 in obesity.
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.